drugset / Trial / NCT06006104

Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer

NCT06006104

Phase 1/2 Unknown 49 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.

Timeline

Start
2023-09-30
Primary completion
2024-09-30
Completion
2024-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-4357 Unknown

Indications